Liver Tumor Program brochure (click to view PDF)

Jing Lan Li, R.N., N.P.
is a Family Nurse Practitioner who
works closely with the multidisciplinary physician group which comprise the Liver Disease Program. She
received her nursing degree from
Rutgers University and a Masters degree in nursing from Pace University.
Fluent in Mandarin and conversant in Cantonese, she is
a nurse manager with more than 20 years experience
working closely with the Chinese community at New
York-Presbyterian/Lower Manhattan Hospital.
Eliza Yue
is an experienced senior patient coordinator for the Liver Disease Program. Eliza is fluent in Cantonese,
and earned her BA is Sociology from
Hunter College. She schedules patient appointments and surgical procedures and coordinates closely with
referring physicians to keep them informed about their
patients’ treatment and to schedule case presentations
for the GI Tumor Board.
GI Tumor Board
The NewYork-Presbyterian/Lower Manhattan GI Oncology
Tumor Board is a monthly meeting of surgeons, radiologists, interventional radiologists, pathologists, gastroenterologists, medical oncologists, radiation oncologists, and
primary care physicians in which patients with complex
gastrointestinal malignancies are discussed in a multidisciplinary forum. At the GI Tumor Board, patients with
complex gastrointestinal malignancies are discussed in a
multidisciplinary forum. Radiographic studies and pathological slides are reviewed and a specific, personalized
treatment plan is developed via group consensus. This
meeting is open to all referring physicians and
we welcome new providers to join us. If you have
a patient that you would like presented at the GI Tumor
Board, please contact Eliza Yue at 646-962-5131 who will
facilitate radiographic and pathologic review and provide
you with the meeting schedule and details.
The Liver Tumor Program is comprised of a multi
disciplinary, dedicated team of specialized healthcare providers offering comprehensive, minimally
invasive surgical and non-surgical services for patients with liver disease. Our Program is committed
to providing seamless, culturally sensitive care to
the Chinese community, which suffers from a higher
incidence of liver disease. It is our goal to provide
patients from the Chinese community with the highest level of care without them having to leave their
neighborhood. Our nurses and medical staff are fluent in both Cantonese and Mandarin. We offer
patients community-based, convenient access to the
unique expertise and pioneering research of highly
trained Weill Cornell physicians. Our Hospital has
been ranked the #1 hospital in the New York area by
US News & World Report for thirteen years in a row.
Referring physicians are considered an integral
part of the treatment team, and we are committed to
ensuring that referring physicians remain involved
in their patients’ care. The results of diagnostic
tests, OR reports and interventional procedures
are communicated to the referring physician immediately after their patient is treated. Our team
will schedule an appointment within a few days of
a referral, and share with the referring physician
an individualized treatment plan which best meets
the patient’s needs. In addition to surgery and interventional radiology, other patient services, such
as liver transplantation, can be coordinated and
facilitated as needed.
of Weill Cornell Medical College specializes in the
comprehensive surgical and non-surgical management of:
• Hepatocellular carcinoma
• Bile duct cancer
• Metastases to the liver from colorectal
and other cancers
• Benign liver neoplasms, including adenoma,
focal nodular hyperplasia and hemangioma
• Pancreatic cancer
• Gallbladder disease and cancer
• Neuroendocrine tumors
Contact Information
The Liver Tumor Program
of Weill Cornell Medical College
156 William Street, 12th Floor
New York, NY 10038
Telephone: (646) 962 - 5131
Fax: (646) 962 - 0157
Dr. Golas: [email protected]
Dr. Li: [email protected]
Dr. Pua: [email protected]
David Li, M.D., Ph.D
is an experienced, board-certified radiologist specializing in
interventional radiology. He is
Assistant Professor of Radiology
and Assistant Attending Radiologist at NewYork-Presbyterian/
Weill Cornell Medical Center.
As a Chinese American, born
and raised in New York City, he
is interested in providing the highest quality of healthcare to the local Chinese community.
Board-certified in diagnostic radiology from the American Board of Radiology, Dr. Li’s clinical expertise is in
interventional radiology. He specializes in the treatment
of liver cancer with the ability to perform procedures
spanning from diagnosis to treatment, including palliation. Minimally invasive procedures include: image
guided needle biopsies; percutaneous tumor ablations
including radiofrequency and microwave ablation;
transarterial embolizations, including chemoembolization, radioembolization and drug-eluting beads; paracentesis and transjugular intrahepatic portosystemic
shunt (TIPS).
Dr. Li’s research interests involve improving upon liver
cancer care by combining pre-existing oncologic therapies in a multidisciplinary setting. He believes that this
approach, in combination with harnessing novel therapeutics which can be targeted to tumors by percutaneous or transarterial means, will further advance the field
of liver cancer treatment.
Dr. Li was awarded his B.S., magna cum laude, in biomedical engineering from Columbia University, New
York, NY. He earned both his M.D. and Ph.D from
the Albert Einstein College of Medicine, Bronx, NY.
Dr. Li was inducted to the Alpha Omega Alpha (AOA)
medical honor society upon graduation. Dr. Li earned
his Master’s degree in physiology and biophysics with
honors prior to completion of his Ph.D. He did a transitional internship year at North Shore University Hospital, Manhasset, NY prior to completing a residency in
diagnostic radiology at Beth Israel Deaconess Medical
Center–Harvard Medical School in Boston, MA. Dr. Li
joined the New York-Presbyterian/Weill Cornell Medical Center Department of Radiology’s faculty after a
year of fellowship training in interventional radiology
at NYP/Weill Cornell.
Bradley B. Pua, M.D.
is Assistant Professor of Radiology and Assistant Attending
Radiologist at NewYork-Presbyterian/Weill Cornell Medical
Center, specializing in interventional radiology. An experienced, board-certified radiologist, Dr. Pua’s clinical expertise
include a wide array of interventional procedures including tumor ablations, arterial embolizations, stent
placements, image-guided biopsies and vascular access. His interests include both pediatric interventions
and minimally invasive cancer therapy, with a particular interest in providing access to high quality care to
the Chinese community.
Dr. Pua obtained a B.S. degree in chemistry from New
York University (NYU) and continued at NYU School of
Medicine where he received his M.D. He completed
three years of surgical residency at New York University Medical Center prior to deciding to pursue a career
in interventional radiology and subsequently completed
a fellowship in interventional radiology at NewYorkPresbyterian/Weill Cornell Medical Center and Memorial Sloan-Kettering Cancer Center. Dr. Pua remained
at NYP/Weill Cornell to complete his diagnostic radiology residency and was selected to serve as chief resident in his final year.
Dr. Pua was the recipient of the Distinguished Housestaff Award from the Weill Cornell Alumni Council and
currently is a reviewer for a variety of journals such as
Radiology, Journal of Vascular and Interventional Radiology and Clinical Imaging. He has published numerous papers and book chapters on a variety of aspects
of minimally invasive cancer care and been invited as
guest editor for seminars in Interventional Radiology.
He is an active member of many prestigious medical
societies including the Society of Interventional Radiology, the Radiologic Society of North America, the Chinese American Medical Society and the Association of
Chinese American Physicians.
Benjamin J. Golas, M.D.
is Assistant Professor of Surgery
and Assistant Attending Surgeon at NewYork-Presbyterian/
Weill Cornell Medical Center.
Dr. Golas is an experienced,
board-certified surgeon, specializing in hepatopancreatobiliary
surgery and surgical oncology.
His practice is conveniently located downtown in the
newly-renovated patient care center at 156 William
Street. Dr. Golas performs the most advanced, minimally invasive surgery at NewYork-Presbyterian/Lower
Manhattan Hospital. His focus is in the treatment of primary liver cancers, metastatic liver lesions, along with
pancreatic and biliary malignancies. Dr. Golas has
strong experience and expertise in laparoscopic procedures for liver cancer, liver metastases, pancreatic
cancer, and other gastrointestinal malignancies.
Dr. Golas received his M.D. from the Georgetown University School of Medicine in Washington, DC, where he
graduated magna cum laude and was elected to the Alpha
Omega Alpha (AOA) medical honor society. He completed
a residency in general surgery at New York-Presbyterian/
Weill Cornell Medical Center, and was selected to serve as
the chief surgical resident. Dr. Golas went on to complete
a fellowship in surgical oncology with advanced specialty
training in liver and pancreatic surgery at the University of
Pittsburgh Medical Center, under the guidance of Dr. David
Geller, a world-renowned hepatobiliary surgeon and a pioneer in the field of laparoscopic liver surgery. He also completed a research fellowship in the laboratory of epithelial
cancer biology at Memorial Sloan-Kettering Cancer Center.
He is a member of several prestigious medical societies, including the Society of Surgical Oncology and the Americas
Hepato-Pancreato-Biliary Association. Dr. Golas has published in multiple scientific journals, was a contributing editor for General Surgery Review, and authored a chapter
entitled “Laparoscopic Liver Resection in the treatment of
Hepatocellular Carcinoma and Colorectal Cancer Liver
Metastases.” He has presented at many national scientific
conferences across the country on minimally invasive surgery for hepatobiliary cancer and advanced surgical treatment for colorectal cancer liver metastases.